Author

Christoph Mancao

Observed names: C. Mancao, Mancao, Christoph

Observed institutions: Roche (Switzerland), Genentech, Helmholtz Munich, Bayer (Switzerland), Innovent Biologics (China), University College London, Bayer (Germany), Ludwig-Maximilians-Universität München

ORCID: 0009-0009-1531-3644

Observed ORCID: 0009-0009-1531-3644

OpenAlex ID: A5000327811

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

2018 · Frederike Bensch, Elly L. van der Veen, et al. · Nature Medicine · 733

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

2017 · Priti S. Hegde, Jeffrey J. Wallin, et al. · Seminars in Cancer Biology · 454

Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival

2007 · Christoph Mancao, Wolfgang Hammerschmidt · Blood · 250

Rescue of “crippled” germinal center B cells from apoptosis by Epstein-Barr virus

2005 · Christoph Mancao, Markus Altmann, et al. · Blood · 201

PDF

Cumulative Burden of Colorectal Cancer–Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer

2019 · Alexi N. Archambault, Yu-Ru Su, et al. · Gastroenterology · 186

Novel Common Genetic Susceptibility Loci for Colorectal Cancer

2018 · Stephanie L Schmit, Christopher K Edlund, et al. · JNCI Journal of the National Cancer Institute · 176

PDF

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

2021 · Yunpeng Yang, Jiya Sun, et al. · Journal of Thoracic Oncology · 146

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

2022 · Jianming Xu, Yi Li, et al. · Nature Communications · 145

PDF

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

2018 · A. Grothey, J. Tabernero, et al. · Annals of Oncology · 101

PDF

Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease

2009 · Jennifer Brewin, Christoph Mancao, et al. · Blood · 93

PDF

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

2018 · H.-G. Wirsching, G. Tabatabai, et al. · Annals of Oncology · 89

PDF

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

2022 · Yuankai Shi, Lin Wu, et al. · 癌症：英文版 · 60

PDF

MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer

2018 · Aparna R. Parikh, Fa-Chyi Lee, et al. · Clinical Cancer Research · 57

Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer

2017 · Oscar Siu Hong Chan, Marcin Kowanetz, et al. · Oral Oncology · 56

Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy

2009 · Sujith Samarasinghe, Christoph Mancao, et al. · Blood · 50

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

2018 · Stéphanie M. Zunder, Gabi W. van Pelt, et al. · British Journal of Cancer · 36

PDF

Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer

2020 · Hiroyuki Arai, Yi Xiao, et al. · Journal for ImmunoTherapy of Cancer · 34

PDF

MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach

2018 · Hans-Joachim Schmoll, Dirk Arnold, et al. · Journal of Cancer Research and Clinical Oncology · 32

MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).

2016 · Heinz-Josef Lenz, Fa-Chyi Lee, et al. · Journal of Clinical Oncology · 30

Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer

2020 · Xiaoju Max Ma, Johanna C. Bendell, et al. · Clinical Cancer Research · 28

PDF

Development of a gene expression–based prognostic signature for IDH wild-type glioblastoma

2020 · Radia M Johnson, Heidi S Phillips, et al. · Neuro-Oncology · 26

PDF

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma

2017 · S. Temam, J. Spicer, et al. · Annals of Oncology · 20

Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials

2023 · Jingyuan Wang, Joshua Millstein, et al. · EClinicalMedicine · 17

Abstract CT017: First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab

2017 · Frederike Bensch, Elly van der Veen, et al. · Cancer Research · 14

Genetic Variants Involved in the cGAS-STING Pathway Predict Outcome in Patients with Metastatic Colorectal Cancer: Data from FIRE-3 and TRIBE Trials

2022 · Jingyuan Wang, Yi Xiao, et al. · European Journal of Cancer · 13

Works count: 132

Citation count: 3,158

H-index: 21

I10-index: 26